SCHEMBL13370786

SCHEMBL13370786

C=C/C=C\C=C/NCC

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13141618 0.89
SCHEMBL17993595 0.89
SCHEMBL13513540 0.89
SCHEMBL13840828 0.77 ADH1B (0.43)
SCHEMBL21012124 0.74
SCHEMBL16481763 0.74 TRPA1 (0.38)
SCHEMBL20334248 0.73 EPHX1 (0.48)
SCHEMBL24326955 0.72
SCHEMBL22996332 0.71
SCHEMBL11167567 0.70

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2010055170-A1 PYRIMIDINIUM DERIVATIVES FOR USE IN THE TREATMENT OR PREVENTION OF DIABETES Technische Universität München (DE) 2010-05-20 WO disclosed
US-20070032653-A1 N-{1-(4-(3-bromophenyl)-1H-imidazol-2-yl)-5-methylhexyl}-N-cyclohexylamine; agonists or antagonists of somatostatin receptors; acromegaly, restenosis, Crohn's disease, systemic sclerosis, external and internal pancreatic pseudocysts and ascites, nesidoblastosis, hyperinsulinism, gastrinoma, etc. SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES, S.A.S. (FR) 2007-02-08 US disclosed